Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-10-18

AUTHORS

Masato Takahashi, Eriko Tokunaga, Joji Mori, Yoshinori Tanizawa, Jan-Stefan van der Walt, Tsutomu Kawaguchi, Matthew P. Goetz, Masakazu Toi

ABSTRACT

BackgroundThis was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC).MethodsEligibility included postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative ABC who had no prior systemic therapy in the advanced disease setting. Patients (N = 493) were randomized 2:1 to receive abemaciclib or placebo (150 mg) plus either 1 mg anastrozole or 2.5 mg letrozole (physician’s choice). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), pharmacokinetics (PK), safety, and health-related quality of life (HRQoL).ResultsIn Japan, 53 patients were randomized (abemaciclib, n = 38; placebo, n = 15). At final PFS analysis (November 3, 2017), median PFS was 29.1 and 14.9 months in the abemaciclib and placebo groups, respectively (hazard ratio 0.537; 95% confidence interval 0.224–1.289). ORR in measurable disease was 62.1 and 50.0% in the abemaciclib and placebo groups, respectively. The Japanese PK profile was comparable to that of the overall population. Consistent with prior studies, the most frequent adverse events reported were diarrhea (abemaciclib: any grade, 94.7%; grade ≥ 3, 10.5%; placebo: any grade, 46.7%; grade ≥ 3, 0%) and neutropenia (abemaciclib: any grade, 68.4%; grade ≥ 3, 21.1%; placebo: any grade, 0%). HRQoL outcomes were generally similar between treatments except for the diarrhea score, which favored placebo.ConclusionsConsistent with findings in the overall population, abemaciclib plus NSAI was an effective initial treatment in the Japanese subpopulation, with a manageable safety profile.Clinical trial registrationNCT02246621; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02246621. More... »

PAGES

174-184

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12282-021-01295-0

DOI

http://dx.doi.org/10.1007/s12282-021-01295-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1141965949

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34661821


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aminopyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anastrozole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aromatase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Letrozole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Progression-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Progesterone", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415270.5", 
          "name": [
            "National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "Masato", 
        "id": "sg:person.012241227304.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012241227304.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470350.5", 
          "name": [
            "National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tokunaga", 
        "givenName": "Eriko", 
        "id": "sg:person.01033234770.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033234770.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly Japan K.K., Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.484107.e", 
          "name": [
            "Eli Lilly Japan K.K., Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mori", 
        "givenName": "Joji", 
        "id": "sg:person.013702327325.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013702327325.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly Japan K.K., Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.484107.e", 
          "name": [
            "Eli Lilly Japan K.K., Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanizawa", 
        "givenName": "Yoshinori", 
        "id": "sg:person.01351423053.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351423053.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Berkshire, UK", 
          "id": "http://www.grid.ac/institutes/grid.418786.4", 
          "name": [
            "Eli Lilly and Company, Berkshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van der Walt", 
        "givenName": "Jan-Stefan", 
        "id": "sg:person.01162003515.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162003515.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly Japan K.K., Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.484107.e", 
          "name": [
            "Eli Lilly Japan K.K., Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawaguchi", 
        "givenName": "Tsutomu", 
        "id": "sg:person.013714314273.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013714314273.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goetz", 
        "givenName": "Matthew P.", 
        "id": "sg:person.014562144757.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014562144757.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Unit, Kyoto University Hospital, Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, 606-8507, Kyoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258799.8", 
          "name": [
            "Breast Cancer Unit, Kyoto University Hospital, Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, 606-8507, Kyoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toi", 
        "givenName": "Masakazu", 
        "id": "sg:person.01331247375.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331247375.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10637-014-0120-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025489180", 
          "https://doi.org/10.1007/s10637-014-0120-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12282-020-01207-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1134631998", 
          "https://doi.org/10.1007/s12282-020-01207-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41523-018-0097-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111375485", 
          "https://doi.org/10.1038/s41523-018-0097-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-018-5054-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110101111", 
          "https://doi.org/10.1007/s10549-018-5054-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-020-06029-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1134291952", 
          "https://doi.org/10.1007/s10549-020-06029-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12282-021-01239-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136859016", 
          "https://doi.org/10.1007/s12282-021-01239-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-10-18", 
    "datePublishedReg": "2021-10-18", 
    "description": "BackgroundThis was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC).MethodsEligibility included postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative ABC who had no prior systemic therapy in the advanced disease setting. Patients (N\u2009=\u2009493) were randomized 2:1 to receive abemaciclib or placebo (150\u00a0mg) plus either 1\u00a0mg anastrozole or 2.5\u00a0mg letrozole (physician\u2019s choice). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), pharmacokinetics (PK), safety, and health-related quality of life (HRQoL).ResultsIn Japan, 53 patients were randomized (abemaciclib, n\u2009=\u200938; placebo, n\u2009=\u200915). At final PFS analysis (November 3, 2017), median PFS was 29.1 and 14.9\u00a0months in the abemaciclib and placebo groups, respectively (hazard ratio 0.537; 95% confidence interval 0.224\u20131.289). ORR in measurable disease was 62.1 and 50.0% in the abemaciclib and placebo groups, respectively. The Japanese PK profile was comparable to that of the overall population. Consistent with prior studies, the most frequent adverse events reported were diarrhea (abemaciclib: any grade, 94.7%; grade \u2265\u20093, 10.5%; placebo: any grade, 46.7%; grade \u2265\u20093, 0%) and neutropenia (abemaciclib: any grade, 68.4%; grade \u2265\u20093, 21.1%; placebo: any grade, 0%). HRQoL outcomes were generally similar between treatments except for the diarrhea score, which favored placebo.ConclusionsConsistent with findings in the overall population, abemaciclib plus NSAI was an effective initial treatment in the Japanese subpopulation, with a manageable safety profile.Clinical trial registrationNCT02246621; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02246621.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12282-021-01295-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1021080", 
        "issn": [
          "1340-6868", 
          "1880-4233"
        ], 
        "name": "Breast Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "keywords": [
      "advanced breast cancer", 
      "objective response rate", 
      "progression-free survival", 
      "nonsteroidal aromatase inhibitor", 
      "human epidermal growth factor receptor", 
      "epidermal growth factor receptor", 
      "initial therapy", 
      "growth factor receptor", 
      "placebo group", 
      "breast cancer", 
      "placebo-controlled phase 3 study", 
      "median progression-free survival", 
      "overall population", 
      "Japanese subgroup analysis", 
      "frequent adverse events", 
      "manageable safety profile", 
      "phase 3 study", 
      "factor receptor", 
      "health-related quality", 
      "effective initial treatment", 
      "final PFS analysis", 
      "MONARCH 3", 
      "measurable disease", 
      "postmenopausal women", 
      "advanced disease", 
      "primary endpoint", 
      "secondary endpoints", 
      "systemic therapy", 
      "adverse events", 
      "HRQOL outcomes", 
      "initial treatment", 
      "safety profile", 
      "subgroup analysis", 
      "aromatase inhibitors", 
      "PFS analysis", 
      "diarrhea score", 
      "abemaciclib", 
      "response rate", 
      "PK profiles", 
      "Japanese subpopulation", 
      "subpopulation analysis", 
      "patients", 
      "therapy", 
      "placebo", 
      "U.S. National Library", 
      "pharmacokinetics", 
      "cancer", 
      "disease", 
      "hormone", 
      "endpoint", 
      "receptors", 
      "treatment", 
      "prior studies", 
      "MethodsEligibility", 
      "neutropenia", 
      "anastrozole", 
      "letrozole", 
      "diarrhea", 
      "BackgroundThis", 
      "group", 
      "population", 
      "months", 
      "women", 
      "study", 
      "survival", 
      "ConclusionsConsistent", 
      "outcomes", 
      "scores", 
      "subpopulations", 
      "inhibitors", 
      "medicine", 
      "safety", 
      "National Library", 
      "profile", 
      "findings", 
      "analysis", 
      "life", 
      "rate", 
      "events", 
      "quality", 
      "Japan", 
      "library"
    ], 
    "name": "Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer", 
    "pagination": "174-184", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1141965949"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12282-021-01295-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34661821"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12282-021-01295-0", 
      "https://app.dimensions.ai/details/publication/pub.1141965949"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_914.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12282-021-01295-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01295-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01295-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01295-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01295-0'


 

This table displays all metadata directly associated to this object as RDF triples.

288 TRIPLES      22 PREDICATES      128 URIs      114 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12282-021-01295-0 schema:about N301313caafa94d37a583e71d303a8b84
2 N39c801e147bd4d029f2106d13ad2a766
3 N74c58084f5da4c63a6d2e217e390c4b8
4 N798827406b31409da15758a81912e791
5 N7a3dd6a57884446abb1ab0ee86b715d7
6 N8155b2f42ec84ae1b66db1317d519fef
7 N854ae44cdb084ac390e329c766b58787
8 N878100ff96ea489b8450cefc32b79839
9 N93480150418f4a05ba3e1d0e47ecfeec
10 N9fb56ed69fd647d68d53526db84b66ad
11 Nbbb36258936743258f8dafd0b1507ca6
12 Ncd3459828f9d409989cb6fc0505cab5c
13 Ncdccc7f3954d45b187038da674d98835
14 Nfb82a59e57454ff9843258209ca93736
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nee962aa61a9d475f93b8b980a18d8dbd
18 schema:citation sg:pub.10.1007/s10549-018-5054-x
19 sg:pub.10.1007/s10549-020-06029-y
20 sg:pub.10.1007/s10637-014-0120-7
21 sg:pub.10.1007/s12282-020-01207-8
22 sg:pub.10.1007/s12282-021-01239-8
23 sg:pub.10.1038/s41523-018-0097-z
24 schema:datePublished 2021-10-18
25 schema:datePublishedReg 2021-10-18
26 schema:description BackgroundThis was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC).MethodsEligibility included postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative ABC who had no prior systemic therapy in the advanced disease setting. Patients (N = 493) were randomized 2:1 to receive abemaciclib or placebo (150 mg) plus either 1 mg anastrozole or 2.5 mg letrozole (physician’s choice). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), pharmacokinetics (PK), safety, and health-related quality of life (HRQoL).ResultsIn Japan, 53 patients were randomized (abemaciclib, n = 38; placebo, n = 15). At final PFS analysis (November 3, 2017), median PFS was 29.1 and 14.9 months in the abemaciclib and placebo groups, respectively (hazard ratio 0.537; 95% confidence interval 0.224–1.289). ORR in measurable disease was 62.1 and 50.0% in the abemaciclib and placebo groups, respectively. The Japanese PK profile was comparable to that of the overall population. Consistent with prior studies, the most frequent adverse events reported were diarrhea (abemaciclib: any grade, 94.7%; grade ≥ 3, 10.5%; placebo: any grade, 46.7%; grade ≥ 3, 0%) and neutropenia (abemaciclib: any grade, 68.4%; grade ≥ 3, 21.1%; placebo: any grade, 0%). HRQoL outcomes were generally similar between treatments except for the diarrhea score, which favored placebo.ConclusionsConsistent with findings in the overall population, abemaciclib plus NSAI was an effective initial treatment in the Japanese subpopulation, with a manageable safety profile.Clinical trial registrationNCT02246621; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02246621.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf Na02c0a3feb7340e29a645ec68f514d5b
31 Nfc8b2b62f2b24bc8b7c20d4a25ed8dbb
32 sg:journal.1021080
33 schema:keywords BackgroundThis
34 ConclusionsConsistent
35 HRQOL outcomes
36 Japan
37 Japanese subgroup analysis
38 Japanese subpopulation
39 MONARCH 3
40 MethodsEligibility
41 National Library
42 PFS analysis
43 PK profiles
44 U.S. National Library
45 abemaciclib
46 advanced breast cancer
47 advanced disease
48 adverse events
49 analysis
50 anastrozole
51 aromatase inhibitors
52 breast cancer
53 cancer
54 diarrhea
55 diarrhea score
56 disease
57 effective initial treatment
58 endpoint
59 epidermal growth factor receptor
60 events
61 factor receptor
62 final PFS analysis
63 findings
64 frequent adverse events
65 group
66 growth factor receptor
67 health-related quality
68 hormone
69 human epidermal growth factor receptor
70 inhibitors
71 initial therapy
72 initial treatment
73 letrozole
74 library
75 life
76 manageable safety profile
77 measurable disease
78 median progression-free survival
79 medicine
80 months
81 neutropenia
82 nonsteroidal aromatase inhibitor
83 objective response rate
84 outcomes
85 overall population
86 patients
87 pharmacokinetics
88 phase 3 study
89 placebo
90 placebo group
91 placebo-controlled phase 3 study
92 population
93 postmenopausal women
94 primary endpoint
95 prior studies
96 profile
97 progression-free survival
98 quality
99 rate
100 receptors
101 response rate
102 safety
103 safety profile
104 scores
105 secondary endpoints
106 study
107 subgroup analysis
108 subpopulation analysis
109 subpopulations
110 survival
111 systemic therapy
112 therapy
113 treatment
114 women
115 schema:name Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
116 schema:pagination 174-184
117 schema:productId N31dff52e74c04a839532fbf3d3c795ee
118 N5b39d341fe9f42bf9c1bdd3a1daae87e
119 Nc021d0385e55441cbb0e77ca577bcbb6
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141965949
121 https://doi.org/10.1007/s12282-021-01295-0
122 schema:sdDatePublished 2022-05-20T07:38
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher Na8d37d58ad8c448880adc3f3396aa928
125 schema:url https://doi.org/10.1007/s12282-021-01295-0
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N301313caafa94d37a583e71d303a8b84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Anastrozole
131 rdf:type schema:DefinedTerm
132 N31dff52e74c04a839532fbf3d3c795ee schema:name pubmed_id
133 schema:value 34661821
134 rdf:type schema:PropertyValue
135 N39c801e147bd4d029f2106d13ad2a766 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Benzimidazoles
137 rdf:type schema:DefinedTerm
138 N453dd1776256467b8ffd430a2834752a rdf:first sg:person.01331247375.47
139 rdf:rest rdf:nil
140 N455fb464fb47459e9329912a4edd7910 rdf:first sg:person.014562144757.35
141 rdf:rest N453dd1776256467b8ffd430a2834752a
142 N52351f3a6fdc4d7bb2e1ad1004d44f8d rdf:first sg:person.01033234770.79
143 rdf:rest Ne4eed85a75004aa5883506c029a85fb4
144 N52ec5d6a7ec74515847543f4d22e6c2e rdf:first sg:person.01351423053.05
145 rdf:rest N7c29f259392c4077b9de035175d040d3
146 N5b39d341fe9f42bf9c1bdd3a1daae87e schema:name doi
147 schema:value 10.1007/s12282-021-01295-0
148 rdf:type schema:PropertyValue
149 N74c58084f5da4c63a6d2e217e390c4b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Progression-Free Survival
151 rdf:type schema:DefinedTerm
152 N798827406b31409da15758a81912e791 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Breast Neoplasms
154 rdf:type schema:DefinedTerm
155 N7a3dd6a57884446abb1ab0ee86b715d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Aminopyridines
157 rdf:type schema:DefinedTerm
158 N7c29f259392c4077b9de035175d040d3 rdf:first sg:person.01162003515.08
159 rdf:rest Nb80a8b703c5a48fbac12449d2de350f5
160 N8155b2f42ec84ae1b66db1317d519fef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Aged
162 rdf:type schema:DefinedTerm
163 N854ae44cdb084ac390e329c766b58787 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Letrozole
165 rdf:type schema:DefinedTerm
166 N878100ff96ea489b8450cefc32b79839 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Middle Aged
168 rdf:type schema:DefinedTerm
169 N93480150418f4a05ba3e1d0e47ecfeec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Receptors, Progesterone
171 rdf:type schema:DefinedTerm
172 N9fb56ed69fd647d68d53526db84b66ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Japan
174 rdf:type schema:DefinedTerm
175 Na02c0a3feb7340e29a645ec68f514d5b schema:issueNumber 1
176 rdf:type schema:PublicationIssue
177 Na8d37d58ad8c448880adc3f3396aa928 schema:name Springer Nature - SN SciGraph project
178 rdf:type schema:Organization
179 Nb80a8b703c5a48fbac12449d2de350f5 rdf:first sg:person.013714314273.17
180 rdf:rest N455fb464fb47459e9329912a4edd7910
181 Nbbb36258936743258f8dafd0b1507ca6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Female
183 rdf:type schema:DefinedTerm
184 Nc021d0385e55441cbb0e77ca577bcbb6 schema:name dimensions_id
185 schema:value pub.1141965949
186 rdf:type schema:PropertyValue
187 Ncd3459828f9d409989cb6fc0505cab5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Aromatase Inhibitors
189 rdf:type schema:DefinedTerm
190 Ncdccc7f3954d45b187038da674d98835 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Humans
192 rdf:type schema:DefinedTerm
193 Ne4eed85a75004aa5883506c029a85fb4 rdf:first sg:person.013702327325.45
194 rdf:rest N52ec5d6a7ec74515847543f4d22e6c2e
195 Nee962aa61a9d475f93b8b980a18d8dbd rdf:first sg:person.012241227304.04
196 rdf:rest N52351f3a6fdc4d7bb2e1ad1004d44f8d
197 Nfb82a59e57454ff9843258209ca93736 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Quality of Life
199 rdf:type schema:DefinedTerm
200 Nfc8b2b62f2b24bc8b7c20d4a25ed8dbb schema:volumeNumber 29
201 rdf:type schema:PublicationVolume
202 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
203 schema:name Medical and Health Sciences
204 rdf:type schema:DefinedTerm
205 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
206 schema:name Clinical Sciences
207 rdf:type schema:DefinedTerm
208 sg:journal.1021080 schema:issn 1340-6868
209 1880-4233
210 schema:name Breast Cancer
211 schema:publisher Springer Nature
212 rdf:type schema:Periodical
213 sg:person.01033234770.79 schema:affiliation grid-institutes:grid.470350.5
214 schema:familyName Tokunaga
215 schema:givenName Eriko
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033234770.79
217 rdf:type schema:Person
218 sg:person.01162003515.08 schema:affiliation grid-institutes:grid.418786.4
219 schema:familyName van der Walt
220 schema:givenName Jan-Stefan
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162003515.08
222 rdf:type schema:Person
223 sg:person.012241227304.04 schema:affiliation grid-institutes:grid.415270.5
224 schema:familyName Takahashi
225 schema:givenName Masato
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012241227304.04
227 rdf:type schema:Person
228 sg:person.01331247375.47 schema:affiliation grid-institutes:grid.258799.8
229 schema:familyName Toi
230 schema:givenName Masakazu
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331247375.47
232 rdf:type schema:Person
233 sg:person.01351423053.05 schema:affiliation grid-institutes:grid.484107.e
234 schema:familyName Tanizawa
235 schema:givenName Yoshinori
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351423053.05
237 rdf:type schema:Person
238 sg:person.013702327325.45 schema:affiliation grid-institutes:grid.484107.e
239 schema:familyName Mori
240 schema:givenName Joji
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013702327325.45
242 rdf:type schema:Person
243 sg:person.013714314273.17 schema:affiliation grid-institutes:grid.484107.e
244 schema:familyName Kawaguchi
245 schema:givenName Tsutomu
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013714314273.17
247 rdf:type schema:Person
248 sg:person.014562144757.35 schema:affiliation grid-institutes:grid.66875.3a
249 schema:familyName Goetz
250 schema:givenName Matthew P.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014562144757.35
252 rdf:type schema:Person
253 sg:pub.10.1007/s10549-018-5054-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1110101111
254 https://doi.org/10.1007/s10549-018-5054-x
255 rdf:type schema:CreativeWork
256 sg:pub.10.1007/s10549-020-06029-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1134291952
257 https://doi.org/10.1007/s10549-020-06029-y
258 rdf:type schema:CreativeWork
259 sg:pub.10.1007/s10637-014-0120-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025489180
260 https://doi.org/10.1007/s10637-014-0120-7
261 rdf:type schema:CreativeWork
262 sg:pub.10.1007/s12282-020-01207-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134631998
263 https://doi.org/10.1007/s12282-020-01207-8
264 rdf:type schema:CreativeWork
265 sg:pub.10.1007/s12282-021-01239-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136859016
266 https://doi.org/10.1007/s12282-021-01239-8
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/s41523-018-0097-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1111375485
269 https://doi.org/10.1038/s41523-018-0097-z
270 rdf:type schema:CreativeWork
271 grid-institutes:grid.258799.8 schema:alternateName Breast Cancer Unit, Kyoto University Hospital, Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, 606-8507, Kyoto, Japan
272 schema:name Breast Cancer Unit, Kyoto University Hospital, Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, 606-8507, Kyoto, Japan
273 rdf:type schema:Organization
274 grid-institutes:grid.415270.5 schema:alternateName National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
275 schema:name National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
276 rdf:type schema:Organization
277 grid-institutes:grid.418786.4 schema:alternateName Eli Lilly and Company, Berkshire, UK
278 schema:name Eli Lilly and Company, Berkshire, UK
279 rdf:type schema:Organization
280 grid-institutes:grid.470350.5 schema:alternateName National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
281 schema:name National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
282 rdf:type schema:Organization
283 grid-institutes:grid.484107.e schema:alternateName Eli Lilly Japan K.K., Kobe, Japan
284 schema:name Eli Lilly Japan K.K., Kobe, Japan
285 rdf:type schema:Organization
286 grid-institutes:grid.66875.3a schema:alternateName Mayo Clinic, Rochester, MN, USA
287 schema:name Mayo Clinic, Rochester, MN, USA
288 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...